Introducing LiquidHALLMARK®

A Swift, Simple and Sensitive Blood Test for Personalized Cancer Care

LiquidHALLMARK is an ultrasensitive next-generation sequencing assay for genomic profiling of a patient’s unique cancer. Requiring only a simple blood sample, LiquidHALLMARK is a broad biomarker panel that is quicker and less invasive compared to tissue biopsies.

 

 

LiquidHALLMARK is a comprehensive, amplicon-based NGS assay for ultrasensitive biomarker detection.

Powered by AmpliMARK, a proprietary amplicon-based sequencing technology, LiquidHALLMARK examines plasma circulating tumor DNA (ctDNA) mutations in 80 genes, including fusions in 10 genes. AmpliMARK is designed to be uniquely sensitive, providing >99% sensitivity at a detection limit of 0.1% Mutant Allele Frequency (MAF). The assay targets single nucleotide variants (including cis-trans), insertions and deletions, copy number variations (CNVs), microsatellite instability (MSI), fusions, and viruses.

LiquidHALLMARK targets have been identified in the following 15 cancers.

Lung
Breast
Colon
Liver
Prostate
Pancreas
Ovarian
Endometrial
Melanoma
Bile Duct
Gastric and Esophageal
GIST
Head and Neck
Nasopharyngeal
Urothelial

LiquidHALLMARK makes genomic profiling easier than ever before.

SWIFT

7-day Turnaround

SIMPLE

1 Blood Draw

SENSITIVE

0.1% Limit of Detection of MAF

Limit of Detection MAFSensitivitySpecificity
Single Nucleotide Variants (SNVs) 0.1 %> 99 %> 99 %
Insertions/ Deletions (Indels) 0.1 %> 95 %> 99 %
Fusions 0.5 %> 90 %> 99 %

AmpliMARK™ Makes the Difference

AmpliMARK is the foundational technology in Lucence’s liquid biopsy tests. AmpliMARK uses a unique molecular barcode and error-correction technology designed to improve test sensitivity across multiple mutation types for single nucleotide variants and fusion genes. Data presented at ASCO20 showed a high sensitivity of AmpliMARK at a limit of detection of 0.1% MAF, achieving high detection of clinically relevant biomarkers in lung, breast and blood cancers. AmpliMARK demonstrated 97.4% concordance for recommended biomarkers when compared with two orthogonal liquid biopsy platforms in lung cancer.

Need Help?